Stryker Co. (NYSE:SYK) Shares Bought by First National Trust Co

First National Trust Co grew its holdings in Stryker Co. (NYSE:SYK - Free Report) by 169.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,380 shares of the medical technology company's stock after purchasing an additional 5,900 shares during the quarter. First National Trust Co's holdings in Stryker were worth $2,809,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of SYK. Royal Fund Management LLC boosted its holdings in shares of Stryker by 4.3% in the 4th quarter. Royal Fund Management LLC now owns 7,952 shares of the medical technology company's stock valued at $2,381,000 after buying an additional 327 shares in the last quarter. AJOVista LLC acquired a new stake in Stryker in the fourth quarter valued at approximately $129,000. Blue Fin Capital Inc. grew its holdings in Stryker by 2.0% in the fourth quarter. Blue Fin Capital Inc. now owns 9,598 shares of the medical technology company's stock worth $2,874,000 after purchasing an additional 185 shares during the last quarter. Legacy Financial Advisors Inc. acquired a new position in shares of Stryker during the fourth quarter worth $227,000. Finally, Sapient Capital LLC purchased a new stake in shares of Stryker during the 4th quarter valued at $1,563,000. Institutional investors own 77.09% of the company's stock.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company's stock, valued at $1,317,414. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director Ronda E. Stryker sold 201,146 shares of the business's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company's stock, valued at $1,287,633,391.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company's stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares of the company's stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on SYK shares. Robert W. Baird upped their target price on Stryker from $367.00 to $378.00 and gave the company an "outperform" rating in a research report on Wednesday. Royal Bank of Canada upped their price objective on shares of Stryker from $360.00 to $386.00 and gave the company an "outperform" rating in a report on Monday, April 15th. BTIG Research lifted their target price on shares of Stryker from $366.00 to $369.00 and gave the stock a "buy" rating in a research note on Wednesday. Canaccord Genuity Group upgraded shares of Stryker from a "hold" rating to a "buy" rating and set a $360.00 price target on the stock in a research note on Wednesday, January 31st. Finally, Piper Sandler lifted their price objective on shares of Stryker from $375.00 to $380.00 and gave the stock an "overweight" rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $365.94.

Stryker Stock Performance

Shares of SYK traded up $1.82 during mid-day trading on Friday, reaching $328.45. The company had a trading volume of 1,589,424 shares, compared to its average volume of 1,415,127. The stock has a 50 day moving average of $346.99 and a two-hundred day moving average of $317.29. The company has a quick ratio of 0.97, a current ratio of 1.71 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $125.12 billion, a P/E ratio of 37.49, a PEG ratio of 2.55 and a beta of 0.91. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, topping analysts' consensus estimates of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The business had revenue of $5.24 billion for the quarter, compared to analysts' expectations of $5.10 billion. During the same quarter last year, the company earned $2.14 EPS. The business's revenue was up 9.7% on a year-over-year basis. On average, analysts expect that Stryker Co. will post 11.94 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th were given a $0.80 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.97%. Stryker's dividend payout ratio (DPR) is currently 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.